Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results) - Vermersch, P.; Eralinna, J.P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; Van Wijmeersch, B.; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. (Journal of the neurological sciences, 2019)